$BAX (Baxter International Inc.)

$BAX {{ '2016-02-16T13:43:19+0000' | timeago}} • Announcement

Drug and medical device maker $BAX said it declared regular quarterly dividend of $0.115 per common share. The cash dividend is payable on April 1 to shareholders of record as of March 4.

$BAX {{ '2017-07-26T12:58:04+0000' | timeago}} • Announcement

$BAX anticipates 2020 adjusted EPS of $3.25-3.40. $BAX also lifted its cash flow expectations for 2020 and now sees operating cash flow of about $2.65Bil. Capital expenditures are expected to total $650MM in 2020, resulting in free cash flow generation of about $2Bil, an increase of $250MM versus prior guidance.

$BAX {{ '2017-07-26T12:56:58+0000' | timeago}} • Announcement

As a result of ongoing business transformation efforts designed to accelerate performance, $BAX lifted its 2020 financial outlook. $BAX expects sales growth of 4% on a compounded annual basis from 2016 to 20202 and now sees adjusted operating margin in 2020 of about 20% as compared to previous guidance of 17-18%.

$BAX {{ '2017-07-26T12:55:25+0000' | timeago}} • Announcement

$BAX expects 3Q17 sales growth of about 4% on a reported basis, about 5% on a constant currency basis and about 6% operationally. The company expects earnings from continuing operations, before special items, of $0.58-0.60 per diluted share.

$BAX {{ '2017-07-26T12:54:23+0000' | timeago}} • Announcement

$BAX lifted 2017 EPS from continuing operations, before special items, guidance to $2.34-2.40 from $2.20-2.28. This guidance assumes the closure of the company's proposed acquisition of Claris Injectables, to be complete by the end of July 2017.

$BAX {{ '2017-07-26T12:52:56+0000' | timeago}} • Announcement

$BAX now expects 2017 sales growth of about 3% on a reported basis, about 4% on constant currency basis and about 5% operationally. Previously, the company had predicted sales growth of about 1-2% on a reported basis or 2-3% on a constant currency basis.

$BAX {{ '2017-07-26T12:46:39+0000' | timeago}} • Announcement

$BAX's renal sales totaled $968MM, comparable to the prior year on reported basis and up 3% on both a constant currency basis and operational basis. Growth was driven by increased sales for in-center hemodialysis (HD) products in the US, international acute renal care sales and global sales of peritoneal dialysis (PD) therapies.

$BAX {{ '2017-07-26T12:45:36+0000' | timeago}} • Announcement

$BAX's global sales for Hospital Products totaled $1.6Bil in 2Q17, rising 1% on reported, 2% on constant currency and 4% operationally. This was driven by continued strength in US fluid systems business, favorable demand for parenteral nutrition therapies and pre-mixed injectable, as well as for select anesthesia and critical care products.

$BAX {{ '2017-07-26T12:42:25+0000' | timeago}} • Announcement

$BAX reported a 78% dip in 2Q17 earnings due to last year's net realized gains from exchange of its retained shares of Baxalta and contribution to its U.S. pension fund. Net income dropped to $265MM or $0.48 per share from $1.21Bil or $2.19 per share last year. Net sales rose 1% to $2.61Bil. Adjusted EPS grew 37% to $0.63.

$BAX {{ '2017-07-18T14:01:55+0000' | timeago}} • Announcement

The BoD of $BAX declared a quarterly dividend of $0.16 per share of its common stock. The dividend is payable on Oct 2, 2017, to stockholders of record as of Sept 1, 2017.

$BAX {{ '2017-07-17T20:58:53+0000' | timeago}} • Announcement

$BAX appointed Cathy Smith, EVP and CFO of $TGT, to its BoD, bringing the total number of directors serving the company at this time to 13. Smith now also serves on $BAX's Audit Committee.

$BAX {{ '2017-06-26T13:13:55+0000' | timeago}} • Announcement

$BAX has announced a bi-directional integration between its software solution DoseEdge Pharmacy Workflow Manager and the Epic Willow Inpatient Pharmacy System. The integration will help hospitals efficiently comply with requirements from the Centers for Medicare and Medicaid Services and other insurers.

$BAX {{ '2017-06-14T12:53:57+0000' | timeago}} • Announcement

$BAX recently announced plans to expand its presence in the space with the pending acquisition of Claris Injectables. The acquisition of Claris is expected to close in 2H17. $BAX recently announced a strategic partnership with ScinoPharm to develop, manufacture and commercialize five generic injectables used in cancer treatment.

$BAX {{ '2017-06-14T12:50:42+0000' | timeago}} • Announcement

$BAX agreed with Dorizoe Lifesciences to facilitate accelerated development of more than 20 generic injectable products, including anti-infectives, oncolytics and cardiovascular medicines. Dorizoe will work with $BAX to perform certain product development activities, and $BAX will hold worldwide manufacturing and commercialization rights.

$BAX {{ '2017-06-07T15:22:17+0000' | timeago}} • Announcement

$BAX announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations. Clindamycin is used to treat serious infections caused by bacteria.

$BAX {{ '2017-06-05T20:30:19+0000' | timeago}} • Announcement

$BAX presented new data demonstrating abilities of its Sharesource remote patient management technology to improve the care of peritoneal dialysis patients and increase dialysis clinic efficiencies. The cloud-based platform offers healthcare providers more accurate and timely visibility to patients’ therapy adherence, allowing timely intervention.

$BAX {{ '2017-06-05T13:03:56+0000' | timeago}} • Announcement

$BAX said data from two independent studies concluded that HDx, or expanded hemodialysis therapy, enabled by the Theranova dialyzer effectively removed small and mid-sized toxins at similar rates when compared to hemodiafiltration (HDF), another type of dialysis.

$BAX {{ '2017-05-02T14:48:04+0000' | timeago}} • Announcement

$BAX BoD has declared a 23% increase in its quarterly dividend rate, from the previous rate of $0.13 per share to $0.16 per share. The dividend is payable on July 3, 2017 to stockholders as of June 2, 2017.

$BAX {{ '2017-04-26T19:39:39+0000' | timeago}} • Webcast

$BAX expects the 20% growth in fluid systems business in the US to come down over time.

$BAX {{ '2017-04-26T19:20:17+0000' | timeago}} • Webcast

$BAX's adjusted operating margin in 1Q17 was up 590 basis points to 16.4%. Growth in the quarter for BAX was impacted by a mid-single-digit decline in hemodialysis globally. Baxter now assumes additional competitors to enter the integrated pharmacy solutions market during 3Q17.

$BAX {{ '2017-04-26T14:18:02+0000' | timeago}} • Infographic

$BAX Baxter International Inc. Earnings AlphaGraphics: Q1 2017 highlights

Recent Transcripts

BAX (Baxter International Inc.)
Wednesday, July 26 2017 - 12:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
CMD (Cantel Medical Corp.)
Thursday, June 8 2017 - 3:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
INFU (InfuSystem Holdings, Inc.)
Friday, May 12 2017 - 1:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
PCRX (Pacira Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
ABC (AmerisourceBergen Corporation)
Thursday, May 4 2017 - 12:30pm
GMED (Globus Medical, Inc.)
Wednesday, May 3 2017 - 9:30pm
ITRI (Itron, Inc.)
Wednesday, May 3 2017 - 9:00pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
AMED (Amedisys Inc.)
Wednesday, May 3 2017 - 3:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm

AlphaGraphics you may like